The Grimm lab in the Molecular Pharmacology Program focuses on the development of novel and innovative molecular imaging approaches for cancer diagnostics, predominantly based on activatable imaging agents. These approaches combine and utilize modern biology, nanotechnology, chemistry and physics with modern imaging methods (MRI, optical imaging, PET and Cerenkov) to create novel imaging agents that allow much earlier detection and improved therapy monitoring of cancer.
Jan Grimm, MD, PhD
Research FocusRadiologist Jan Grimm develops novel activatable molecular imaging approaches for improved detection and monitoring of prostate and other cancers.
- MD, University of Hamburg (Germany)
- PhD, University of Kiel (Germany)
- In our latest paper, published in Nano Letters on “Silica Nanoparticles as Substrates for Chelator-free Labeling of Oxophilic Radioisotopes”, we describe a method for facile chelator-free radiometal labeling of silica nanoparticles, which allows for a widespread of applications. This work is in collaboration with the Kircher Lab.
- In our paper, published in Nature Communications on March 4, 2014, we show that a clinically approved iron oxide nanoparticle (Ferumoxytol) can be used as pH-sensitive drug delivery vehicle, and that drug loading and release can be monitored in vivo by magnetic resonance imaging.